# PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Source: https://onco.cc/key-papers/paper-keynote-017-n-engl-j-med-2016/  
OnCo record `paper-keynote-017-n-engl-j-med-2016` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Published report from the KEYNOTE-017 trial registered as NCT02267603, in New England Journal of Medicine (2016), chosen as the most cited paper whose own text cites the registry id.

## Summary

Background: Merkel-cell carcinoma is an aggressive skin cancer that is linked to exposure to ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell carcinoma often responds to chemotherapy, but responses are transient. Blocking the programmed death 1 (PD-1) immune inhibitory pathway is of interest, because these tumors often express PD-L1, and MCPyV-specific T cells express PD-1.

Methods: In this multicenter, phase 2, noncontrolled study, we assigned adults with advanced Merkel-cell carcinoma who had received no previous systemic therapy to receive pembrolizumab (anti-PD-1) at a dose of 2 mg per kilogram of body weight every 3 weeks. The primary end point was the objective response rate according to Response Evaluation Criteria in Solid Tumors, version 1.1. Efficacy was correlated with tumor viral status, as assessed by serologic and immunohistochemical testing.

Results: A total of 26 patients received at least one dose of pembrolizumab. The objective response rate among the 25 patients with at least one evaluation during treatment was 56% (95% confidence interval [CI], 35 to 76); 4 patients had a complete response, and 10 had a partial response. With a median follow-up of 33 weeks (range, 7 to 53), relapses occurred in 2 of the 14 patients who had had a response (14%). The response duration ranged from at least 2.2 months to at least 9.7 months. The rate of progression-free survival at 6 months was 67% (95% CI, 49 to 86). A total of 17 of the 26 patients (65%) had virus-positive tumors. The response rate was 62% among patients with MCPyV-positive tumors (10 of 16 patients) and 44% among those with virus-negative tumors (4 of 9 patients). Drug-related grade 3 or 4 adverse events occurred in 15% of the patients.

Conclusions: In this study, first-line therapy with pembrolizumab in patients with advanced Merkel-cell carcinoma was associated with an objective response rate of 56%. Responses were observed in patients with virus-positive tumors and those with virus-negative tumors. (Funded by the National Cancer Institute and Merck; ClinicalTrials.gov number, NCT02267603.).

Indexed on Europe PMC as PubMed record 27093365 (DOI 10.1056/nejmoa1603702). Its abstract cites the registry id NCT02267603, which is how it was matched to this trial; no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: New England Journal of Medicine
- Year: 2016
- DOI: 10.1056/nejmoa1603702
- Authors: Nghiem PT, Bhatia S, Lipson EJ, et al.
- What it means: This is the paper Europe PMC returns for registry id NCT02267603 with the most citations, so it is the natural first reading for anyone following the KEYNOTE-017 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
- Caveats: Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.

## Sources

- N Engl J Med 2016: https://doi.org/10.1056/nejmoa1603702
- PubMed: https://pubmed.ncbi.nlm.nih.gov/27093365/
- Europe PMC: https://europepmc.org/article/MED/27093365
- ClinicalTrials.gov NCT02267603: https://clinicaltrials.gov/study/NCT02267603

## Connected records

- trials: [KEYNOTE-017 (Cancer Immunotherapy Trials Network 09)](https://onco.cc/trials/keynote-017/)
- journals: [New England Journal of Medicine](https://onco.cc/journals/nejm/)
- people: [Shailender Bhatia](https://onco.cc/people/shailender-bhatia/)

---
JSON: https://onco.cc/api/v1/entities/paper-keynote-017-n-engl-j-med-2016.json